Daptomycin gel - NanoReviv
Alternative Names: Staph-ExLatest Information Update: 15 Mar 2024
At a glance
- Originator NanoReviv
- Class Antibacterials; Cyclic peptides; Lipopeptides; Peptide antibiotics
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Bone and joint infections
Most Recent Events
- 15 Mar 2024 Pharmacodynamics and adverse events data from preclinical trial in Bone and joint infections released by NanoReviv, before March 2024 (NanoReviv website, March 2024)
- 14 Mar 2024 Daptomycin gel - NanoReviv is available for licensing as of 14 Mar 2024. https://www.nanoreviv.com/products/ (NanoReviv website, March 2024)
- 14 Mar 2024 Preclinical trials in Bone and joint infections in France (unspecified route), before March 2024 (NanoReviv website, March 2024)